

Docket No. 209794US0



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: William M. CANFIELD

SERIAL NO: 10/024,197

GAU: 1652

FILED: December 21, 2001

EXAMINER: SLOBODYANSKY, E.

FOR: HIGHLY PHOSPHORYLATED ACID BETA-GLUCOCEREBROSIDASE AND METHODS OF TREATING GAUCHER'S DISEASE

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☒ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment form is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Richard L. Chinn

Registration No. 34,305

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Daniel J. Pereira, Ph.D.

Registration No. 45,518

09/10/2003 EAREGAY1 00000011 10024197

03 FC:1806

180.00 OP

Docket No. 209794US0



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: William M. CANFIELD

SERIAL NO: 10/024,197

GAU: 1652

FILED: December 21, 2001

EXAMINER: SLOBODYANSKY, E.

FOR: HIGHLY PHOSPHORYLATED ACID BETA-GLUCOCEREBROSIDASE AND METHODS OF TREATING GAUCHER'S DISEASE

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment form is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Richard L. Chinn

Registration No. 34,305

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Daniel J. Pereira, Ph.D.

Registration No. 45,518

Form PTO 1449  
(Modified)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

209794US77

SERIAL NO.

10/024,197

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

William M. CANFIELD

FILING DATE

December 21, 2001

GROUP

1652



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	NO
	AQ				
	AP				
	AQ				
	AR				
	AS				
	AT				
	AU				
	AV				

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

AW	R. O. BRADY, et al., "Modifying Exogenous Glucocerebrosidase for Effective Replacement Therapy in Gaucher", J. Inher. Metab. Dis., Vol. 17, (1994), pp. 510-519
AX	Emil D. KAKKIS, et al., "Overexpression of the Human Lysosomal Enzyme $\alpha$ -L-Iduronidase in Chinese Hamster Ovary Cells", Protein Expression and Purification, Vol. 5, (1994), pp.225-232
AY	Ke-Wei ZHAO, et al., "Carbohydrate Structures of Recombinant Human $\alpha$ -L-Iduronidase Secreted by Chinese Hamster Ovary Cells", The Journal of Biological Chemistry, Vol. 272, No. 36, Issue of September 5, pp.22758-22765 (1997)
AZ	Robin J. ZIEGLER, et al., "Correction of Enzymatic and Lysosomal Storage Defects in Fabry Mice by Adenovirus-Mediated Gene Transfer", Human Gene Therapy, Vol. 10, pp.1667-1682, (July 1, 1999)

Examiner

Date Considered

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449  
(Modified)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

209794US77

SERIAL NO.

10/024,197

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

William M. CANFIELD

FILING DATE

December 21, 2001

GROUP

1652

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						
	BM						
	BN						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	NO
	BO					
	BQ					
	BR					
	BS					
	BT					
	BU					
	BV					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	BW	Huaichang SUN, et al., "Retrovirus Vector-Mediated Correction and Cross-Correction of Lysosomal $\alpha$ -Mannosidase Deficiency in Human and Feline Fibroblasts", Human Gene Therapy, Vol. 10, pp. 1311-1319, (May 20, 1999)
	BX	Ajj REUSER, et al., "Lysosomal storage diseases: cellular pathology, clinical and genetic heterogeneity, therapy", Ann Biol Clin, (1994), Vol. 52, pp. 721-728
	BY	
	BZ	

Examiner

Date Considered

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.